CYDY News and Press, CytoDyn Inc From 08/04/20

VANCOUVER, Washington, Aug. 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company, announced today an independent Data Safety Monitoring Committee (“DSMC”) completed its first safety re...

VANCOUVER, Washington, July 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

In response to the current worldwide pandemic, CytoDyn ( CYDY ) is frenetically tracking down an FDA approval for its monoclonal antibody, leronlimab in treatment of COVID-19. I was initially quite skeptical of this quest, but I have slowly warmed to the prospect. As matters now stand, I am ...

FinancialBuzz.com News Commentary New York, NY (7/27/2020) – The wearable technology ecosystem continues to rapidly evolve around the world as several technological developments help stir up demand. The medical technology sector, among others such as biotechs developing vaccines and med...

VANCOUVER, Washington, July 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

The Proposition The proposition of Cytodyn ( CYDY ) is that its humanized monoclonal antibody molecule, leronlimab, which blocks the CCR5 receptor on T cells and macrophages can prevent cytokine and chemokine mischief including metastasis and in the present results, the cytokine storms in th...

Disclaimer: This report is the work of an investment adviser affiliated with the author. The report is the result of the adviser executing its investment strategy. The adviser holds a position in the security, however there is no assurance that the adviser will continue to hold the investm...

39% (11 SAEs in 28 Patients) in Placebo Arm as Compared to Only 14% (8 SAEs in 56 Patients) in Leronlimab Arm Reported Serious Adverse Events (SAEs), Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will Be Announced Along With a Full Report as Soon as Statistical Anal...

39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs, Which Were Unrelated to Leronlimab. The Efficacy Portion of the Trial Will be Announced Along With a Full Report as Soon as Statistical Analyses are Completed Evaluation of safety ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...